Polyclonal Antibody to Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1)
| Code | Size | Price |
|---|
| PAF219Hu02-20ul | 20ul | £87.00 |
Quantity:
| PAF219Hu02-100ul | 100ul | £162.00 |
Quantity:
| PAF219Hu02-200ul | 200ul | £218.00 |
Quantity:
| PAF219Hu02-1ml | 1ml | £499.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
M6S1; NPP1; NPPS; PC-1; PCA1; PDNP1; Membrane component chromosome 6 surface marker 1; Alkaline phosphodiesterase I; Plasma-cell membrane glycoprotein PC-1
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Ectonucleotide Pyrophosphatase/Phosphodiesterase 1
Reactivity:
Mu;Ra;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-3ug/mL;<br/>Immunohistochemistry: 5-30ug/mL;<br/>Immunocytochemistry: 5-30ug/mL;<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) | RPF219Hu02 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||